SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT00542789

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase III, Multicentre, Randomised, Double-blind, Parallel-group, Comparative Efficacy and Safety Study of Esomeprazole(20 mg Once Daily) Versus Placebo for the Prevention of Gastric and/or Duodenal Ulcers Associated With Daily Nonsteroidal Anti-inflammatory Drug (NSAID) Use

The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers

NCT00542789 Gastric Ulcer Duodenal Ulcer Rheumatoid Arthritis Osteoarthritis Lumbago
MeSH: Osteoarthritis Arthritis, Rheumatoid Ulcer Stomach Ulcer Duodenal Ulcer
HPO: Duodenal ulcer Gastric ulcer Osteoarthritis Rheumatoid arthritis

2 Interventions

Name: Esomeprazole

Description: 20mg once daily oral

Type: Drug

2

Name: Placebo

Description: once daily oral

Type: Drug

1


Primary Outcomes

Description: The absence of gastric and/or duodenal ulcer throughout the treatment period

Measure: Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period

Time: each visit up to 24 weeks

Secondary Outcomes

Description: The absence of gastric and/or duodenal ulcer up to 4 weeks after treatment

Measure: Absence of Gastric and/or Duodenal Ulcer up to 4 Weeks After Treatment

Time: up to 4 weeks

Description: The absence of gastric and/or duodenal ulcer up to 12 weeks after treatment

Measure: Absence of Gastric and/or Duodenal Ulcer up to 12 Weeks After Treatment

Time: up to 12 weeks

Purpose: Prevention

Allocation: Randomized

Parallel Assignment


There is one SNP

SNPs


1 D961H

Comparative Efficacy & Safety Study of Esomeprazole Versus Placebo for the Prevention of Gastric and Duodenal Ulcers With NSAID The purpose of this study is to assess the efficacy of esomeprazole (D961H) 20 mg versus placebo once daily for up to 24 weeks of treatment involving patients with a history of gastric and/or duodenal ulcers receiving daily nonsteroidal anti-inflammatory drug (NSAID) therapy by evaluating presence or absence of gastric and/or duodenal ulcers throughout the treatment period (24 weeks) in terms of efficacy on prevention of gastric and/or duodenal ulcers Absence of Gastric and/or Duodenal Ulcer Throughout the Treatment Period. --- D961H ---



HPO Nodes


HPO:
Duodenal ulcer
Genes 2
ARID1B PLG
Gastric ulcer
Genes 4
ARID1B ERGIC1 CISD2 WFS1
Osteoarthritis
Genes 52
COL2A1 COL3A1 GHR PHEX TGFB3 CCN6 GDF5 COL5A1 HGD COL5A2 COL9A1 COL9A2 COL9A3 COL11A1 COL11A2 FBN1 ATP7B ZMPSTE24 UFSP2 COMP LMNA CLCN7 AEBP1 CANT1 LMX1B SLC26A2 ACAN HPGD MATN3 SCARB2 TRPS1 GBA TRPV4 EXT1 EXT2 FGFR3 AIP GNAS GPR101 MMP13 ANKH TNXB F8 SLC40A1 F9 MEFV ZNF687 SMAD3 KIF22 KIF7 COL1A1 TRAPPC2
Rheumatoid arthritis
Genes 14
DCLRE1C IL2RA IL2RB LACC1 PTPN2 ANKRD55 PTPN22 IL6 GCH1 HLA-DRB1 ACP5 CD247 STAT4 MIF